Invivo Capital Partners logo

Invivo Capital Partners

Europe, Catalonia, Spain, Barcelona

Description

Invivo Capital is a management firm that invests in startup healthcare enterprises.

Investor Profile

Invivo Capital Partners has backed more than 18 startups, with 3 new investments in the last 12 months alone. The firm has led 8 rounds, about 44% of its total and boasts 0 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Seed, Series Unknown, Series A rounds (top funding stages).
  • Majority of deals are located in Spain, France, Belgium.
  • Strong thematic focus on Biotechnology, Pharmaceutical, Therapeutics.
  • Led 1 rounds in the past year.

Stage Focus

  • Seed (56%)
  • Series Unknown (22%)
  • Series A (17%)
  • Series B (6%)

Country Focus

  • Spain (61%)
  • France (22%)
  • Belgium (6%)
  • Denmark (6%)

Industry Focus

  • Biotechnology
  • Pharmaceutical
  • Therapeutics
  • Life Science
  • Health Care
  • Agriculture
  • Genetics
  • Financial Services
  • Insurance
  • Food And Beverage
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Invivo Capital Partners frequently co-invest with?

AdBio partners
Europe, Ile-de-France, France, Paris
Co-Investments: 3
Omnes Capital
Europe, Ile-de-France, France, Paris
Co-Investments: 2
Fountain Healthcare Partners
North America, New York, United States, New York
Co-Investments: 1
V-Bio Ventures
Europe, Oost-Vlaanderen, Belgium, Gent
Co-Investments: 2
Kurma Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 2
Jeito Capital
Europe, Ile-de-France, France, Paris
Co-Investments: 1
JC
Europe, Catalonia, Spain, Badalona
Co-Investments: 2
NC
Europe, Catalonia, Spain, Barcelona
Co-Investments: 2
CDTI
North America, California, United States, Ventura
Co-Investments: 1
Co-Investments: 3

What are some of recent deals done by Invivo Capital Partners?

ARTHEx Biotech

Valencia, Comunidad Valenciana, Spain

AntagomiR oligonucleotides to treat Myotonic Dystrophy patients.

Biotechnology
Series BSep 17, 2025
Amount Raised: $40,640,000
Integra Therapeutics

Barcelona, Catalonia, Spain

Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases.

BiotechnologyGeneticsHealth Care
SeedSep 8, 2025
Amount Raised: $12,541,948

Signadori Bio is the next-generation cellular immunotherapy for cancer cure.

ManufacturingPharmaceutical
Series UnknownMar 18, 2025
Neumirna Therapeutics

Copenhagen, Hovedstaden, Denmark

Neumirna Therapeutics is a Danish pharmaceutical start-up based in Copenhagen.

Pharmaceutical
Series AJan 8, 2025
Amount Raised: $20,708,264
Gyala Therapeutics

Barcelona, Catalonia, Spain

Gyala Therapeutics is focused on developing new CAR-T therapies for treating hematological malignancies.

BiotechnologyLife ScienceTherapeutics
Series UnknownOct 14, 2024
EsoBiotec

Mont-saint-guibert, Brabant Wallon, Belgium

soBiotec is a Belgian biotechnology business focused on the discovery of novel cancer therapies.

Biotechnology
Series ADec 12, 2023
Amount Raised: $2,159,699
Corteria Pharmaceuticals

Paris, Ile-de-France, France

Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations.

BiotechnologyPharmaceuticalTherapeutics
Series ASep 7, 2023
Amount Raised: $69,538,574
OneChain Immunotherapeutics

Barcelona, Catalonia, Spain

OCI develops therapies for leukaemia based on CAR–T.

BiotechnologyLife Science
SeedJun 22, 2023
Amount Raised: $7,340,197
ARTHEx Biotech

Valencia, Comunidad Valenciana, Spain

AntagomiR oligonucleotides to treat Myotonic Dystrophy patients.

Biotechnology
Series BMay 3, 2023
Amount Raised: $46,487,689
Atekka

Paris, Ile-de-France, France

Atekka is a new generation agricultural insurance company.

AgricultureFinancial ServicesInsurance
Series UnknownSep 19, 2022
Amount Raised: $4,914,803